Key result
Sacubitril/valsartan in HFrEF is linked to improved HRV and a ~3 bpm lower 24-hour heart rate.
Why the study?
Sacubitril/Valsartan improves outcomes in HFrEF, but its effect on cardiac autonomic balance using physiological sensor data from ICDs or CRT-Ds required investigation.
Does Sacubitril/Valsartan improve cardiac autonomic function and reduce ventricular arrhythmias in patients with HFrEF and ICD/CRT-Ds?
Does Sacubitril/Valsartan improve cardiac autonomic function and reduce ventricular arrhythmias in patients with HFrEF and ICD/CRT-Ds?
Sacubitril/Valsartan initiation in HFrEF patients is associated with early improvements in cardiac autonomic function, evidenced by increased heart rate variability and decreased heart rate.
Should not yet change HFrEF prescribing; hypothesis-generating for autonomic effects and needs randomized confirmation.
Background/Objectives: Sacubitril/Valsartan is a cornerstone therapy to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the effect of Sacubitril/Valsartan on cardiac autonomic balance using physiological sensor data obtained from implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy defibrillators (CRT-Ds). Methods: This observational study involved 54 ICD and CRT-D patients who initiated Sacubitril/Valsartan therapy to treat HFrEF. The evaluated key parameters included heart rate variability (HRV), 24 h mean heart rate (24 h-HR), and nocturnal heart rate (nHR). Device electrical parameters and ventricular arrhythmias were also assessed. The data were collected by remote monitoring and averaged over a 7-day window at baseline (before treatment) and at 3 and 12 months after treatment initiation. Results: Sacubitril/Valsartan significantly improved HRV at 3 months (from 78.6 ms [interquartile range: 54.2–104.6] to 80.8 ms [60.8–108.0]; p = 0.041), reduced 24 h-HR (from 73.2 bpm [67.3–77.7] to 69.9 bpm [64.2–75.7]; p = 0.016), and reduced nHR (from 63.0 bpm [58.1–70.0] to 60.4 bpm [56.0–68.6]; p = 0.028). No significant changes in HRV, 24 h-HR, and nHR were observed between 3- and 12-month follow-up. The device electrical parameters were not influenced by the treatment. While the overall ventricular arrhythmia burden did not change post-treatment, patients with pre-treatment arrhythmias experienced a significant reduction in episodes from 2.97 (pre-treatment) to 0.82 (post-treatment) events per 100 patient years (p = 0.008). Conclusions: Sacubitril/Valsartan therapy in HFrEF patients was associated with statistically significant changes in cardiac autonomic indices, including a small increase in HRV and a slight reduction in heart rate, mainly during the first three months of treatment.
No takes yet. Share an insight, caveat, or question.
Lema et al. (2026) studied this question. Sacubitril/Valsartan therapy improved heart rate variability by 2.2 ms and reduced 24h mean heart rate by 3.3 bpm at 3 months in patients with HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: